Skip to main content
Premium Trial:

Request an Annual Quote

mtm laboratories Raises Additional $15.3M in Series C Financing

NEW YORK (GenomeWeb News) – Heidelberg, Germany-based mtm laboratories said today that it has raised an additional €9.6 million ($15.3 million) in its Series C round of private financing.
The investment marks the third tranche in the Series C round, which has brought in a total of €31.6 million.
mtm said it will use the funds to expand clinical and commercial development for its p16INK4a biomarker-based tests CINtec and Cervatec. CINtec is being developed to detect overexpression of the biomarker in biopsies and cervical cytology specimens. Its recently launched Cervatec assay uses ELISA technology for detection of pINK4a over-expression.
HBM BioVentures and HBM BioCapital led the Series C round, with additional investments from Wellington Partners, Mannheim Holdings, Heidelberg Innovation, Nexus Medical Partners, and new investor National Technology Enterprises Company of Kuwait, which contributed €2.25 million to the most recent tranche.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.